Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-Current Assets (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Non-Current Assets for 13 consecutive years, with $60.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 74.64% to $60.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $506.9 million, a 48.34% decrease, with the full-year FY2024 number at $193.1 million, changed N/A from a year prior.
  • Non-Current Assets was $60.8 million for Q3 2025 at Theravance Biopharma, up from $59.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $277.2 million in Q1 2023 to a low of $59.7 million in Q2 2025.
  • A 5-year average of $186.3 million and a median of $206.0 million in 2022 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: soared 137.67% in 2022, then tumbled 75.39% in 2025.
  • Theravance Biopharma's Non-Current Assets stood at $105.9 million in 2021, then skyrocketed by 139.7% to $253.9 million in 2022, then dropped by 0.8% to $251.9 million in 2023, then dropped by 23.34% to $193.1 million in 2024, then crashed by 68.53% to $60.8 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Non-Current Assets are $60.8 million (Q3 2025), $59.7 million (Q2 2025), and $193.3 million (Q1 2025).